Retinitis PigmentosaPhase 1/2NCT05712148
Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa
A Phase 1/2 study testing Stem cell implantation in people with Retinitis Pigmentosa and Stem Cell Transplant, run by Acibadem University at 1 site in Turkey (Türkiye).
Trial summary
Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem cell therapy for retinitis pigmentosa (RP) patients with relatively good visual acuity. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Retinitis Pigmentosa, Stem Cell Transplant
- What is being tested?
- Stem cell implantation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 11 Oct 2019to 14 Jun 2022
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- 1) Clinical and genetic diagnosis of Retinitis Pigmentosa
Who cannot join
- Coexisting ocular pathology that may affect visual acuity, visual field and retinal morphology such as glaucoma, uveitis, previous vitreoretinal surgery,
- Coexisting cataract that may affect mfERG, visual field and/or ocular imaging,
- Refractive error that may affect measurements higher than +6.00D, lower than -6.00D
- Coexisting systemic diseases that may affect visual function such as diabetes, vasculitis, rheumatological diseases and chronic immunosuppressive use,
- Periocular injection of platelet-rich blood and transcorneal electrical stimulation in previous 6 months and 6) previous ocular surgery
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Suprachoroidal Spheroidal Mesenchymal Stem Cell Implantation in Retinitis Pigmentosa: Clinical Results of 6 Months Follow-up
Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem cell therapy for retinitis pigmentosa (RP) patients with relatively good visual acuity.
Methods: Fifteen eyes of 15 patients with RP who received suprachoroidal implantation of MSCs in the form of spheroids were included. Best corrected visual acuity (BCVA), 10-2 and 30-2 visual field examination and multifocal electroretinography (mfERG) recordings were recorded at baseline, postoperative first, third- and sixth-months during follow-up.
Read the detailed description
A prospective clinical trial was conducted in patients with RP at the department of ophthalmology, Acibadem University, Medical school. The study was approved by the Review Board of Cell, Organ and Tissue Transplantation Department of Turkish Ministry of Health. The study was performed in accordance with the Declaration of Helsinki.
Patient Evaluation Fifteen patients with clinical and genetic diagnoses of RP were included in the study. Patients underwent ophthalmic examination including best corrected visual acuity (BCVA), intraocular pressure, anterior segment examination and dilated fundus examination (with topical tropicamide %1 and phenylephrine 2.5%). Each eye underwent spectral domain OCT scanning with Cirrus 5000 HD-OCT Angioplex (Carl Zeiss Meditec, Dublin, CA, USA), fundus autofluorescence and fundus fluorescein angiography (Heidelberg Engineering, Germany). MD (mean deviation) and PSD (pattern standard deviation) parameters of 10-2 and 30-2 visual field (VF) testing strategies with a Humphrey Field Analyzer model 750I (Carl Zeiss Meditec, Dublin, CA, USA) were obtained. The electrophysiological function was assessed with mfERG evaluation (Monpack 3, Metrovision, France) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines [27]. BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) equivalent.
The patients were excluded from the study, if they had 1) coexisting ocular pathology that may affect visual acuity, visual field and retinal morphology such as glaucoma, uveitis, previous vitreoretinal surgery, 2) coexisting cataract that may affect mfERG, visual field and/or ocular imaging, 3) refractive error that may affect measurements higher than +6.00D, lower than -6.00D 4) coexisting systemic diseases that may affect visual function such as diabetes, vasculitis, rheumatological diseases and chronic immunosuppressive use, 5) periocular injection of platelet-rich blood and transcorneal electrical stimulation in previous 6 months and 6) previous ocular surgery.
Electrophysiologic Testing After 30 minutes of dark adaptation and pupil dilatation with the application of one drop of tropicamide 1% (Tropamid, Bilim ˙Ilaç, Turkey), phenylephrine 2.5% (Mydfrin, Alcon), and proparacaine hydrochloride 0.5% (Alcaine, Alcon), ERG jet electrodes were placed. Multifocal electroretinographies were recorded after pupil dilatation. The stimulated retinal area was subtended in an area of 60° x 55°; 61 hexagon stimulants were used with alternating black (5 cd/m2) and white (100 cd/m2) stimulants. The concentric rings were analyzed according to International Society for Clinical Electrophysiology of Vision standards.13 The amplitude and latencies of P1, N1, and N2 components were recorded for every ring. The mean signal amplitudes (MSAs) of multifocal electroretinography (mfERG) in the macula (central 0°-2°) and the peripheral (2°-5°,5°-10°, 10°-15°, and >15°) signal amplitude changes were evaluated separately.
Spheroidal Stem Cell Preparation First passage umbilical cord-derived mesenchymal stem cell was obtained from Labcell Cellular Laboratory Center which provides GMP (good manufacturing practices) conditions.
Spheroid Production The spheroid production continued in GMP condition. First passage umbilical cord-derived mesenchymal stem cells were used in the production of spheroids. 100,000 mesenchymal stem cells were suspended with 100 μl. Serum-free medium (MSC NutriStem® XF Medium, Sartorius) containing %1 ciprofloxacin (Polipharma). Each well of the low-attachment 96 well plate was seeded with 100,000 cells in 100 μl. medium. The cells were incubated at 37 °C for 48 hours. At the end of 48 hours, all spheroids were collected with a micropipette and transferred into Ringer's lactate solution (Osel/ Biofleks) containing 1% HSA (csl behring). Spheroids were washed 3 times with Ringer's lactate solution containing 1% HAS (csl behring). 50 spheroids were produced for one patient (50 spheroids containing 5x106 cells were produced). 5 of 50 spheroids were reserved for quality control analysis. The remaining 45 spheroid membranes were embedded in the matrix.
Matrix Production and Cell Embedding Culture Matrix mixture containing 225 µl cryoprecipitate + 22.5 µl calcium (Adeka) + 2.5 µl transamine (Haver) was added to each well of the 96 well plates. When the matrix became semi-solid, 45 spheroids were embedded in the middle of the matrix and incubated at 37 °C for 45 min. The matrix, which became completely solid after 45 minutes, was removed with the help of a scalpel, transferred into Ringer's lactate solution (Osel/ Biofleks) containing 1% HAS (csl behring), and transferred to the operating room in this solution (Figure 1).
Quality Control Analysis Microbiological blood culture, fungal, endotoxin analysis and purity (ciprofloxacin <0,1 µg/ml), efficiency (adipocyte and cartilage differentiation analysis) Cell Count/Viability and flow cytometric analysis (CD34 <%2, CD45 <%4, CD90 >%80, HLA-DR <%4, CD105 >%60, CD73 >%70) were studied from the reserved spheroids for quality control analyses.
Surgical Technique Patients underwent surgery under general anesthesia. The inferotemporal quadrant was chosen as the surgical area. 6.0 silk was used as the anchoring suture near the limbus between 4 and 5 o'clock. Conjunctiva and tenon were opened as 6 mm long cut at 6 mm from limbus parallel to the limbus and the edges of the cut were advanced 3 mm posteriorly. Two 8.0 vicryl sutures were used as traction sutures at the anterior corners of the conjunctiva. The tenon was dissected over the sclera posteriorly. Then we performed a 7x7 scleral flap. Anterior margin of the scleral flap was created at 8 mm from the limbus, parallel to the limbus with 30 degrees ophthalmic knife. Two other half-thickness side cuts were made to create a U-shaped flap that has its base parallel to the lateral rectus muscle. Then starting from the infero-anterior edge, a deep scleral flap was dissected with a crescent blade. During the dissection black choroidal reflex should be observed all around the surface of the flap bed. The fibrin plug carrying spheroidal stem cells was placed over the choroid that was seen under the thin sclera. It was covered by the scleral flap and the flap was sutured to its original position from its edges with a 7.0 vicryl suture. Tenon and conjunctiva were closed separately with an 8.0 vicryl suture.
- Conditions
- Retinitis Pigmentosa, Stem Cell Transplant
- Being tested
- Stem cell implantation
- Keywords
- Retinitis pigmentosa, Mesenchymal stem cells, Spheroids, Suprachoroidal implantation
- Medical subject headings
- Retinitis Pigmentosa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stem cell implantationBiological
Suprachoridal mesenchymal spheroidal stem cell implantation
| Study group | Role | What they receive |
|---|---|---|
| Retinitis Pigmentosa patients | Experimental | Suprachoroidal mesenchymal stem cell implanted Retinitis pigmentosa patients Receives: Biological: Stem cell implantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in visual acuity after stem cell implantation in Retinitis Pigmentosa
Pre-implantation and post-implantation BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) equivalent.
Measured: 3 years
Change in microperimetric evaluation after stem cell implantation in Retinitis Pigmentosa
MD (mean deviation) and PSD (pattern standard deviation) parameters of 10-2 and 30-2 visual field (VF) testing strategies with a Humphrey Field Analyzer model 750I (Carl Zeiss Meditec, Dublin, CA, USA) were obtained.
Measured: 3 years
Change in electrophysiological testing after stem cell implantation in Retinitis Pigmentosa
The electrophysiological function was assessed with mfERG evaluation (Monpack 3, Metrovision, France) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines.After 30 minutes of dark adaptation and pupil dilatation with the application of one drop of tropicamide 1% (Tropamid, Bilim ˙Ilaç, Turkey), phenylephrine 2.5% (Mydfrin, Alcon), and proparacaine hydrochloride 0.5% (Alcaine, Alcon), ERG jet electrodes were placed. Multifocal electroretinographies were recorded after pupil dilatation. The concentric rings were analyzed according to International Society for Clinical Electrophysiology of Vision standards. The amplitude and latencies of P1, N1, and N2 components were recorded for every ring. The mean signal amplitudes (MSAs) of multifocal electroretinography (mfERG) in the macula (central 0°-2°) and the peripheral (2°-5°,5°-10°, 10°-15°, and >15°) signal amplitude changes were evaluated separately.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2023
- Study start11 Oct 2019
- Primary completion30 Jan 2022
- Study completion14 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinitis PigmentosaStudies of the same condition, open and under way.
- More trials run by Acibadem UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Acibadem University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Berna Özkan, Acibadem University
- Investigators
- Berna Özkan, Professor, Principal investigator, Acibadem UniversityErcüment Ovalı, Professor, Study chair, Acıbadem LabCell Cellular Therapy Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05712148
- Sponsor's protocol ID
- 56733164/203 E.3858
- Status last verified
- Jan 2023
- First submitted
- 16 Jan 2023
- Last updated
- 3 Feb 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Suprachoroidal Spheroidal Mesenchymal Stem Cell Implantation in Retinitis Pigmentosa: Clinical Results of 6 Months Follow-up
- ClinicalTrials.gov ID
- NCT05712148
- Acronym / sponsor ID
- 56733164/203 E.3858
- Conditions
- Retinitis Pigmentosa, Stem Cell Transplant
- Keywords
- Retinitis pigmentosa, Mesenchymal stem cells, Spheroids, Suprachoroidal implantation
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Acibadem UniversityUniversity, hospital or other
- Study start
- 11 Oct 2019 (actual)
- Primary completion
- 30 Jan 2022 (actual)
- Study completion
- 14 Jun 2022 (actual)
- First posted
- 3 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem cell therapy for retinitis pigmentosa (RP) patients with relatively good visual acuity.
Methods: Fifteen eyes of 15 patients with RP who received suprachoroidal implantation of MSCs in the form of spheroids were included. Best corrected visual acuity (BCVA), 10-2 and 30-2 visual field examination and multifocal electroretinography (mfERG) recordings were recorded at baseline, postoperative first, third- and sixth-months during follow-up.
Detailed description
A prospective clinical trial was conducted in patients with RP at the department of ophthalmology, Acibadem University, Medical school. The study was approved by the Review Board of Cell, Organ and Tissue Transplantation Department of Turkish Ministry of Health. The study was performed in accordance with the Declaration of Helsinki.
Patient Evaluation Fifteen patients with clinical and genetic diagnoses of RP were included in the study. Patients underwent ophthalmic examination including best corrected visual acuity (BCVA), intraocular pressure, anterior segment examination and dilated fundus examination (with topical tropicamide %1 and phenylephrine 2.5%). Each eye underwent spectral domain OCT scanning with Cirrus 5000 HD-OCT Angioplex (Carl Zeiss Meditec, Dublin, CA, USA), fundus autofluorescence and fundus fluorescein angiography (Heidelberg Engineering, Germany). MD (mean deviation) and PSD (pattern standard deviation) parameters of 10-2 and 30-2 visual field (VF) testing strategies with a Humphrey Field Analyzer model 750I (Carl Zeiss Meditec, Dublin, CA, USA) were obtained. The electrophysiological function was assessed with mfERG evaluation (Monpack 3, Metrovision, France) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines [27]. BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) equivalent.
The patients were excluded from the study, if they had 1) coexisting ocular pathology that may affect visual acuity, visual field and retinal morphology such as glaucoma, uveitis, previous vitreoretinal surgery, 2) coexisting cataract that may affect mfERG, visual field and/or ocular imaging, 3) refractive error that may affect measurements higher than +6.00D, lower than -6.00D 4) coexisting systemic diseases that may affect visual function such as diabetes, vasculitis, rheumatological diseases and chronic immunosuppressive use, 5) periocular injection of platelet-rich blood and transcorneal electrical stimulation in previous 6 months and 6) previous ocular surgery.
Electrophysiologic Testing After 30 minutes of dark adaptation and pupil dilatation with the application of one drop of tropicamide 1% (Tropamid, Bilim ˙Ilaç, Turkey), phenylephrine 2.5% (Mydfrin, Alcon), and proparacaine hydrochloride 0.5% (Alcaine, Alcon), ERG jet electrodes were placed. Multifocal electroretinographies were recorded after pupil dilatation. The stimulated retinal area was subtended in an area of 60° x 55°; 61 hexagon stimulants were used with alternating black (5 cd/m2) and white (100 cd/m2) stimulants. The concentric rings were analyzed according to International Society for Clinical Electrophysiology of Vision standards.13 The amplitude and latencies of P1, N1, and N2 components were recorded for every ring. The mean signal amplitudes (MSAs) of multifocal electroretinography (mfERG) in the macula (central 0°-2°) and the peripheral (2°-5°,5°-10°, 10°-15°, and >15°) signal amplitude changes were evaluated separately.
Spheroidal Stem Cell Preparation First passage umbilical cord-derived mesenchymal stem cell was obtained from Labcell Cellular Laboratory Center which provides GMP (good manufacturing practices) conditions.
Spheroid Production The spheroid production continued in GMP condition. First passage umbilical cord-derived mesenchymal stem cells were used in the production of spheroids. 100,000 mesenchymal stem cells were suspended with 100 μl. Serum-free medium (MSC NutriStem® XF Medium, Sartorius) containing %1 ciprofloxacin (Polipharma). Each well of the low-attachment 96 well plate was seeded with 100,000 cells in 100 μl. medium. The cells were incubated at 37 °C for 48 hours. At the end of 48 hours, all spheroids were collected with a micropipette and transferred into Ringer's lactate solution (Osel/ Biofleks) containing 1% HSA (csl behring). Spheroids were washed 3 times with Ringer's lactate solution containing 1% HAS (csl behring). 50 spheroids were produced for one patient (50 spheroids containing 5x106 cells were produced). 5 of 50 spheroids were reserved for quality control analysis. The remaining 45 spheroid membranes were embedded in the matrix.
Matrix Production and Cell Embedding Culture Matrix mixture containing 225 µl cryoprecipitate + 22.5 µl calcium (Adeka) + 2.5 µl transamine (Haver) was added to each well of the 96 well plates. When the matrix became semi-solid, 45 spheroids were embedded in the middle of the matrix and incubated at 37 °C for 45 min. The matrix, which became completely solid after 45 minutes, was removed with the help of a scalpel, transferred into Ringer's lactate solution (Osel/ Biofleks) containing 1% HAS (csl behring), and transferred to the operating room in this solution (Figure 1).
Quality Control Analysis Microbiological blood culture, fungal, endotoxin analysis and purity (ciprofloxacin <0,1 µg/ml), efficiency (adipocyte and cartilage differentiation analysis) Cell Count/Viability and flow cytometric analysis (CD34 <%2, CD45 <%4, CD90 >%80, HLA-DR <%4, CD105 >%60, CD73 >%70) were studied from the reserved spheroids for quality control analyses.
Surgical Technique Patients underwent surgery under general anesthesia. The inferotemporal quadrant was chosen as the surgical area. 6.0 silk was used as the anchoring suture near the limbus between 4 and 5 o'clock. Conjunctiva and tenon were opened as 6 mm long cut at 6 mm from limbus parallel to the limbus and the edges of the cut were advanced 3 mm posteriorly. Two 8.0 vicryl sutures were used as traction sutures at the anterior corners of the conjunctiva. The tenon was dissected over the sclera posteriorly. Then we performed a 7x7 scleral flap. Anterior margin of the scleral flap was created at 8 mm from the limbus, parallel to the limbus with 30 degrees ophthalmic knife. Two other half-thickness side cuts were made to create a U-shaped flap that has its base parallel to the lateral rectus muscle. Then starting from the infero-anterior edge, a deep scleral flap was dissected with a crescent blade. During the dissection black choroidal reflex should be observed all around the surface of the flap bed. The fibrin plug carrying spheroidal stem cells was placed over the choroid that was seen under the thin sclera. It was covered by the scleral flap and the flap was sutured to its original position from its edges with a 7.0 vicryl suture. Tenon and conjunctiva were closed separately with an 8.0 vicryl suture.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Retinitis Pigmentosa patients | Experimental | Biological: Stem cell implantationSuprachoroidal mesenchymal stem cell implanted Retinitis pigmentosa patients |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- 1) Clinical and genetic diagnosis of Retinitis Pigmentosa
Key exclusion criteria (5 listed)
- Coexisting ocular pathology that may affect visual acuity, visual field and retinal morphology such as glaucoma, uveitis, previous vitreoretinal surgery,
- Coexisting cataract that may affect mfERG, visual field and/or ocular imaging,
- Refractive error that may affect measurements higher than +6.00D, lower than -6.00D
- Coexisting systemic diseases that may affect visual function such as diabetes, vasculitis, rheumatological diseases and chronic immunosuppressive use,
- Periocular injection of platelet-rich blood and transcorneal electrical stimulation in previous 6 months and 6) previous ocular surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stem cell implantationSuprachoridal mesenchymal spheroidal stem cell implantation | Biological | Retinitis Pigmentosa patients |
Primary outcome
Change in visual acuity after stem cell implantation in Retinitis Pigmentosa
Time frame: 3 years
Pre-implantation and post-implantation BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) equivalent.
Change in microperimetric evaluation after stem cell implantation in Retinitis Pigmentosa
Time frame: 3 years
MD (mean deviation) and PSD (pattern standard deviation) parameters of 10-2 and 30-2 visual field (VF) testing strategies with a Humphrey Field Analyzer model 750I (Carl Zeiss Meditec, Dublin, CA, USA) were obtained.
Change in electrophysiological testing after stem cell implantation in Retinitis Pigmentosa
Time frame: 3 years
The electrophysiological function was assessed with mfERG evaluation (Monpack 3, Metrovision, France) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines.After 30 minutes of dark adaptation and pupil dilatation with the application of one drop of tropicamide 1% (Tropamid, Bilim ˙Ilaç, Turkey), phenylephrine 2.5% (Mydfrin, Alcon), and proparacaine hydrochloride 0.5% (Alcaine, Alcon), ERG jet electrodes were placed. Multifocal electroretinographies were recorded after pupil dilatation. The concentric rings were analyzed according to International Society for Clinical Electrophysiology of Vision standards. The amplitude and latencies of P1, N1, and N2 components were recorded for every ring. The mean signal amplitudes (MSAs) of multifocal electroretinography (mfERG) in the macula (central 0°-2°) and the peripheral (2°-5°,5°-10°, 10°-15°, and >15°) signal amplitude changes were evaluated separately.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Retinitis Pigmentosa
RecruitingObservational study
Rod and Cone Mediated Function in Retinal Disease
Retinal Degeneration, Retinitis Pigmentosa
RecruitingObservational study
Cell Collection to Study Eye Diseases
Retinal Disease, AMD
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
RecruitingObservational study
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Inherited Retinal Degeneration, Retinitis Pigmentosa
Active, not recruitingObservational study
Rate of Progression in EYS Related Retinal Degeneration
Retinitis Pigmentosa, Eye Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Berna Özkan, Professor principal investigator
Acibadem University
Ercüment Ovalı, Professor study chair
Acıbadem LabCell Cellular Therapy Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Stem cell implantation in people with Retinitis Pigmentosa and Stem Cell Transplant, run by Acibadem University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in visual acuity after stem cell implantation in Retinitis Pigmentosa (time frame: 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2023.